PriceTargets.com logo

Emergent BioSolutions - EBS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.00
  • Forecasted Upside: 168.82%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.86 As of 04/18/2024 01:00 AM ET
▼ -0.04 (-2.11%)

This chart shows the closing price for EBS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Emergent BioSolutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EBS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EBS

Analyst Price Target is $5.00
▲ +168.82% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Emergent BioSolutions in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 168.82% upside from the last price of $1.86.

This chart shows the closing price for EBS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Emergent BioSolutions. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024BenchmarkReiterated RatingBuy ➝ Buy$5.00Low
3/7/2024BenchmarkUpgradeHold ➝ Buy$5.00Low
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweightLow
8/29/2023BenchmarkDowngradeBuy ➝ HoldLow
4/10/2023BenchmarkUpgradeHold ➝ Buy$22.00Low
3/17/2023JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$23.00 ➝ $9.00Low
11/15/2022CowenLower Target$25.00Low
11/10/2022BenchmarkDowngradeBuy ➝ HoldLow
11/9/2022Chardan CapitalLower TargetBuy$65.00 ➝ $55.00Low
9/12/2022CowenLower TargetMarket Perform$30.00 ➝ $29.00Low
9/12/2022CowenLower TargetMarket Perform$30.00 ➝ $29.00Low
5/4/2022Wells Fargo & CompanyLower Target$46.00 ➝ $38.00Medium
4/29/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
4/29/2022CowenLower Target$40.00 ➝ $30.00High
4/29/2022CowenLower Target$40.00 ➝ $30.00High
4/29/2022Chardan CapitalLower Target$75.00 ➝ $65.00High
3/10/2022Wells Fargo & CompanyBoost TargetEqual Weight$37.00 ➝ $40.00High
1/20/2022Cantor FitzgeraldBoost Target$50.00 ➝ $55.00High
1/20/2022BenchmarkUpgradeHold ➝ Buy$77.00High
11/10/2021Chardan CapitalLower TargetBuy$92.00 ➝ $75.00Low
11/8/2021BenchmarkDowngradeBuy ➝ HoldHigh
5/11/2021ArgusReiterated RatingBuy ➝ HoldN/A
5/5/2021Wells Fargo & CompanyLower Target$70.00 ➝ $64.00Low
5/5/2021ArgusDowngradeBuy ➝ HoldHigh
4/30/2021Chardan CapitalLower TargetBuy$112.00 ➝ $92.00Medium
4/30/2021BenchmarkLower TargetHold ➝ Buy$150.00 ➝ $120.00Medium
4/14/2021GuggenheimLower TargetBuy$130.00 ➝ $110.00Medium
4/7/2021BenchmarkInitiated CoverageBuy$150.00Low
2/24/2021Chardan CapitalUpgradeNeutral ➝ Buy$112.00Low
2/19/2021Chardan CapitalDowngradeBuy ➝ Neutral$112.00High
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$110.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
7/31/2020Chardan CapitalBoost TargetBuy$86.00 ➝ $112.00High
7/17/2020Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $110.00High
7/2/2020Wells Fargo & CompanyBoost TargetOverweight$85.00 ➝ $93.00Medium
6/8/2020Chardan CapitalReiterated RatingBuy$86.00Low
6/8/2020Cantor FitzgeraldLower TargetOverweight$86.00 ➝ $85.00High
6/8/2020GuggenheimLower TargetBuy$101.00 ➝ $87.00High
6/2/2020GuggenheimBoost Target$81.00 ➝ $101.00Low
6/1/2020Chardan CapitalReiterated RatingBuy$86.00High
5/6/2020ArgusBoost TargetBuy$67.00 ➝ $90.00Low
5/1/2020Cantor FitzgeraldBoost TargetOverweight$75.00 ➝ $86.00High
5/1/2020Chardan CapitalBoost TargetBuy$71.00 ➝ $86.00High
4/30/2020Wells Fargo & CompanyBoost TargetOverweight$75.00 ➝ $85.00Low
4/24/2020Chardan CapitalReiterated RatingBuy$71.00High
3/12/2020CowenInitiated CoverageHold$67.00Medium
3/1/2020CowenReiterated RatingHold$67.00Low
2/25/2020Wells Fargo & CompanyBoost TargetOverweight$66.00 ➝ $75.00Medium
11/25/2019CowenReiterated RatingHold$67.00High
11/22/2019Cantor FitzgeraldReiterated RatingOverweight$75.00High
11/7/2019Wells Fargo & CompanyReiterated RatingBuyMedium
11/7/2019Chardan CapitalReiterated RatingBuy$71.00High
11/7/2019CowenReiterated RatingHold$67.00High
9/12/2019GuggenheimInitiated CoverageBuy$65.00Low
9/4/2019LaidlawSet TargetBuy$72.00Low
9/4/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$61.00 ➝ $64.00High
9/3/2019Chardan CapitalSet TargetBuy$71.00Low
7/31/2019CowenReiterated RatingHold$60.00High
5/10/2019Wells Fargo & CompanyLower TargetMarket Perform$61.00Medium
5/3/2019CowenReiterated RatingHold$60.00High
5/2/2019Cantor FitzgeraldReiterated RatingBuy$75.00High
4/21/2019Cantor FitzgeraldReiterated RatingBuy$75.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 6 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/20/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Emergent BioSolutions logo
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $1.86
Low: $1.83
High: $1.99

50 Day Range

MA: $2.39
Low: $1.53
High: $3.41

52 Week Range

Now: $1.86
Low: $1.42
High: $10.92

Volume

1,061,146 shs

Average Volume

2,736,983 shs

Market Capitalization

$97.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Emergent BioSolutions?

The following equities research analysts have issued research reports on Emergent BioSolutions in the last year: Benchmark Co., JPMorgan Chase & Co., and StockNews.com.
View the latest analyst ratings for EBS.

What is the current price target for Emergent BioSolutions?

1 Wall Street analysts have set twelve-month price targets for Emergent BioSolutions in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 168.8%. Benchmark Co. has the highest price target set, predicting EBS will reach $5.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $5.00 for Emergent BioSolutions in the next year.
View the latest price targets for EBS.

What is the current consensus analyst rating for Emergent BioSolutions?

Emergent BioSolutions currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EBS, but not buy more shares or sell existing shares.
View the latest ratings for EBS.

What other companies compete with Emergent BioSolutions?

Other companies that are similar to Emergent BioSolutions include Bolt Biotherapeutics, Regulus Therapeutics, Fortress Biotech, Rigel Pharmaceuticals and Vanda Pharmaceuticals. Learn More about companies similar to Emergent BioSolutions.

How do I contact Emergent BioSolutions' investor relations team?

Emergent BioSolutions' physical mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company's listed phone number is (240) 631-3200 and its investor relations email address is [email protected]. The official website for Emergent BioSolutions is www.emergentbiosolutions.com. Learn More about contacing Emergent BioSolutions investor relations.